Boston — Studion said it has promoted Brian Harrington to General Manager of its Life Sciences business unit.
In the expanded role, Harrington will lead strategy, growth and delivery for Studion’s end-to-end eClinical services, helping life sciences organizations accelerate time to market for new treatments.
Studion is a technology services company that designs and builds digital experiences for learning and life sciences clients.
The company said Harrington brings experience in the clinical trials market and has helped build teams and partnerships across the digital health ecosystem. In his previous role in Commercial Development, he worked across customer success and operations to strengthen client relationships and develop service offerings for Studion clients.
“Brian’s understanding of the complexity of clinical trial technology and his ability to think creatively about how to solve it makes him the ideal leader for our Life Sciences business unit,” said Furqan Nazeeri, CEO at Studion. “This promotion reflects our continued commitment to being a trusted partner to our clients and a leader in eClinical tech services, including our new managed services offerings for study start-up and study maintenance.”
Studion’s Life Sciences business unit provides platform-agnostic eClinical services and has designed, built and tested more than 2,000 eCOA, eConsent and EDC solutions across multiple therapeutic areas.
The company said Harrington’s appointment comes as demand for compliant, patient-centered eClinical solutions in clinical trials continues to grow.
“I’m honored to step into this role at such an exciting time for both Studion and the life sciences industry,” said Harrington. “As the eClinical landscape continues to evolve, our clients are looking for more strategic, scalable ways to deliver with confidence. While staff augmentation remains an important part of our business, I’m especially excited about the continued growth of our study start-up and maintenance managed service offerings. These offerings help eCOA and eClinical companies improve financial and operational predictability, reduce costs, and help bring life-changing therapies to patients faster.”
